On 6 month 1 day, the American efficacy skincare brand Obagi changes hands again. European private equity fund Bridgepoint acquires Obagi's dermatological skincare and medical aesthetics business from Waldencast at a maximum price of 4.6 hundred million US dollars (approximately RMB 31.2 hundred million yuan).
Who is Obagi? Founded in 1988 by American dermatologist Zein E. Obagi, it primarily targets physician prescription channels. As the first efficacy skincare brand in the United States to receive FDA certification, it is known alongside SkinCeuticals and ZO Skin Health as one of the three giants of American efficacy skincare.
At its peak, Obagi was listed on NASDAQ in 2006, ranked first in the United States in sales market share in 2015, and topped the prescription medical skincare product category for 20 consecutive years. The brand holds 62 patents, operates in more than 80 countries and regions worldwide, and has won the favor of over 3 ten thousand dermatologists. Even in recent years it has maintained growth, with net revenue of 1.49 hundred million US dollars (approximately RMB 10.07 hundred million yuan) in fiscal year 2024, a year-on-year increase of 26.9%.
However, such an efficacy skincare brand with nearly forty years of history and a top position in the professional field has repeatedly changed ownership under the impetus of capital. This is already the fourth ownership change since the brand was founded 38 years ago.
What deserves more attention than the transaction itself is its timing.Waldencast brought Obagi under its umbrella through a SPAC merger in 2022, and has held it for less than four years.Less than half a year before the sale, Obagi had just launched an FDA-approved injectable filler product line, and the brand was promoting a super brand strategy.
Why did Waldencast choose to exit at this time? Behind this transaction lies how capital logic repeatedly rewrites brand destiny in the efficacy skincare track.
Waldencast held Obagi for less than four years before hastily transferring it, which is the most unusual and questionable aspect of this transaction. To understand this sale, we must go back to the capital boom of 2022.
At that time, Waldencast, founded by former L'Oréal executives, packaged Obagi and the makeup brand Milk Makeup together through a backdoor listing, and landed on NASDAQ with a total valuation of approximately 12 hundred million US dollars (approximately RMB 86.4 hundred million yuan). This price was clearly high. Based on the financial data at that time, Obagi's annual net sales were approximately 1.79 hundred million US dollars (approximately RMB 12.9 hundred million yuan), meaning the market value was 6.7 times sales. The capital market was willing to pay such a high price simply because it saw the bright prospects of a multi-brand beauty platform.
But after the capital boom faded, the fragility of the high-leverage model quickly became apparent.Waldencast's financial situation is not optimistic. In fiscal year 2025, the company's net revenue was only 2.72 hundred million US dollars (approximately RMB 19.6 hundred million yuan), and adjusted profit was only 1610 ten thousand US dollars (approximately RMB 1.16 hundred million yuan), with considerable profit pressure. At the same time, the company still carries approximately 1.49 hundred million US dollars (approximately RMB 10.7 hundred million yuan) in debt and urgently needs cash to improve its balance sheet.
In fact, before officially selling Obagi, Waldencast had already begun asset dismantling. In 2025 month 11, Obagi's trademark rights in Japan were sold for 8250 ten thousand US dollars (approximately RMB 5.94 hundred million yuan), with the proceeds used to repay debt. In the first quarter of 2026, Obagi's newly launched filler incurred approximately 530 ten thousand US dollars (approximately RMB 3816 ten thousand yuan) in launch costs, further increasing the short-term financial burden.Various signs indicate that the sale of Obagi was not a sudden transaction, but a systematic asset cleanup by Waldencast under financial pressure.
The management arrangements also reveal more information.After the transaction is completed, Waldencast's two co-founders will leave the original company and instead co-lead the Obagi business with Bridgepoint.This means that Waldencast as a platform company no longer intends to operate this brand, and the two founders have changed from platform owners to operators being transferred. Waldencast originally packaged itself as a brand integrator, but now it has effectively degenerated into an asset disposer.
▍Waldencast co-founders Michel Brousset and Hind Sebti
From the perspective of capital operations, it is not difficult to understand why Waldencast transferred it so quickly. When listing through a backdoor, it needed to tell a sufficiently attractive growth story to support its market value, and Obagi played a key role in that story. But when the capital market winds shifted and debt pressure rose, the significance of continuing to hold the brand changed from strategic layout to financial burden. Selling Obagi was not because the brand itself had problems, but because continuing to hold it no longer met Waldencast's short-term financial needs as a listed company. Obagi was instrumentalized here; its existence merely provided liquidity for the parent company's capital maneuvering.
To understand Obagi's current situation, it is worth rewinding the timeline to 38 years ago. The four ownership changes outline a clear trajectory: the brand has always been a chess piece in capital transactions, not the place where capital ultimately wants to go.
The first ownership change occurred in 1997. Founder Zein Obagi founded the brand in 1988, and quickly established a professional reputation with prescription-grade skincare products sold through physician channels. But less than ten years later, the founder sold all his shares, and control of the brand fell into the hands of external investors. This was the starting point of the brand's capitalization.
The second ownership change was the Valeant era from 2013 to 2017. Canadian pharmaceutical company Valeant bought Obagi for 3.44 hundred million US dollars (approximately RMB 24.8 hundred million yuan) and completed privatization. But this deal lasted only four years. In 2017, Valeant transferred Obagi to a fund under Haitong International for 1.9 hundred million US dollars (approximately RMB 13.7 hundred million yuan), a price reduction of nearly 45%. Valeant's stated reason was to simplify business, reduce debt, and focus on core business. This is a common phrase used by capital parties when disposing of non-core assets.
The third ownership change lasted from 2017 to 2022, when Obagi entered the Chinese capital period. During Haitong International's holding, the brand entered the Chinese market in 2018, but never established a stable operational system. During this period, Obagi's global business maintained growth, but its performance in the Chinese market remained lukewarm.
The fourth ownership change is this transfer from Waldencast to Bridgepoint. Unlike before, this holding period is the shortest, and the valuation logic is the most complex. Looking solely at the figure of 4.6 hundred million US dollars (approximately 33.1 hundred million yuan), it is still an increase over Valeant's purchase price of 3.44 hundred million US dollars (approximately 24.8 hundred million yuan). But if one considers inflation, the brand's expansion in product lines and global market coverage, and the high valuation expectations at the time of the backdoor listing in 2022, this price is not impressive. The pricing of approximately 3 times annual sales has clearly fallen compared with the peak period of consumer brand mergers and acquisitions in 2022.
A noteworthy phenomenon is that with each ownership change, the brand's operations team and strategic direction undergo an adjustment. The Valeant era emphasized coordination with pharmaceutical channels, the Haitong International era attempted to open the Chinese market, and the Waldencast era stressed the synergistic effects of a multi-brand platform. Each adjustment requires time and resources, but the time capital holds the brand often does not allow these strategies to fully unfold. Obagi is like a relay baton, constantly passed among capital, and each handover is accompanied by the interruption and restart of brand strategy.
If the global capital rotation is Obagi's universal story, then the Chinese market offers a more ironic observation angle. A brand with Chinese capital ties has walked an unusually difficult path in China's efficacy skincare track.
Obagi's Chinese ties are real. After being acquired by Haitong International in 2017, the brand in fact became an enterprise with Chinese capital background. As of the end of 2024, Obagi Greater China CEO Dai Sicong still indirectly held Waldencast equity and was the largest shareholder of the listed company. This blood relationship should have been a natural advantage for Obagi to conquer the Chinese market.
Reality is the opposite. In 2024, Obagi's China business plummeted 50% year-on-year, with annual revenue of only 280 ten thousand US dollars (approximately 2016 ten thousand yuan). At the same time, Obagi China operating companies and subsidiaries were successively sued by enterprises such as Kaichun Co., Ltd. and Sinopharm Holding Distribution Center, and some subsidiaries were listed as dishonest judgment debtors with frozen equity. Offline agents reported that low-priced products existed online, far below their purchase prices, and related issues were not promptly resolved by the brand. Channel chaos, price collapse, and partnership breakdown are typical symptoms of management losing control during rapid expansion.
In sharp contrast to Obagi is SkinCeuticals, also a leading American professional skincare brand. The two, together with ZO Skin Health, are known as the three giants of American efficacy skincare and enjoy equal reputation among American dermatologists. But after SkinCeuticals was acquired by L'Oréal in 2010, it received group-level channel resources, brand building, and consumer education support in the Chinese market, gradually establishing a stable price system and professional reputation. Obagi, however, due to control constantly switching between Chinese capital and backdoor listing platforms, never formed stable strategic focus in its Chinese operations.
A rather dramatic detail is the misalignment of timing. In 2024 12, Obagi grandly established a new retail headquarters in Changzhou, making a big push into live-streaming e-commerce and smart supply chains, with no small support from local government. Yet less than a year and a half later, the brand was again put up for sale by its parent company. From heavy investment in China to rapid divestment, this rhythm itself illustrates the problem: there is a profound mismatch between the brand's strategic decisions and the capital's exit pace.
Obagi is about to enter the Bridgepoint era. This European private equity fund already has a presence in the medical aesthetics and dermatology fields, including an investment in French filler company Laboratoires Vivacy and a previous acquisition of skincare brand RoC Skincare. Bridgepoint's healthcare head explicitly stated that the acquisition of Obagi is built on its growing dermatology, medical aesthetics, and skincare ecosystem, with deep cooperation possible in the future.
This means Obagi may no longer be an isolated brand in the hands of its new owner, but a key piece of a larger map. The strategy of ecosystem integration has its rationale. Obagi's physician channel resources and professional skincare product line can create synergies with other medical aesthetics assets under Bridgepoint. The FDA-approved filler Saypha MagIQ launched in the first quarter of 2026 made Obagi the first beauty super brand covering both skincare and injectables, a strategic positioning highly compatible with Bridgepoint's medical aesthetics portfolio.
But the risks are equally obvious. The typical holding period of private equity funds is 5 to 7 years. Under a financial framework with exit as the ultimate goal, brand operation decisions constantly face the tug between short-term financial pressure and long-term brand building. Obagi's super brand strategy, extending from skincare to injectable fillers, requires long-term R&D investment, physician education investment, and consumer trust building, all of which need time and patience. The return cycle of private equity funds determines that they cannot wait indefinitely like family businesses or long-term strategic investors.
A variable worth watching is management continuity. Waldencast's two co-founders, Broussard and Sebti, will transfer to Bridgepoint simultaneously and continue to co-lead the Obagi business. This arrangement helps maintain brand strategy stability and avoid a management vacuum caused by ownership change. But Bridgepoint's exit clock cannot be avoided, and Obagi may well face a fifth ownership change. In the private equity script, the brand is ultimately an asset to be sold at a price.
Obagi's four ownership changes reveal a deep contradiction. Efficacy skincare brands naturally need long-term nurturing: scientific research takes time, physician relationships need accumulation, and consumer trust needs patient cultivation. But the logic of capital is cyclical. Whether Valeant's debt relief, Haitong International's China layout, Waldencast's backdoor listing arbitrage, or Bridgepoint's private equity exit mechanism, all exert pressure for change at the moments when the brand most needs stability.
Brands and capital are not inherently opposed. But when capital's relay race runs faster than brand building, the brand becomes the baton constantly passed around. Obagi's 38-year history is essentially a history of capital will repeatedly rewriting the brand's fate. In the hands of the new owner, whether it can break out of this cycle of repeated ownership changes depends on whether Bridgepoint has the willingness and ability to transform Obagi from a bargaining chip into a true brand empire.
At a time when the efficacy skincare track is increasingly crowded and professional thresholds continue to rise, this may be a common question for all efficacy skincare brands and the capital behind them.